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Abstract 
 
BACKGROUND AND PURPOSE: Prostate cancer is the second leading cause of 
cancer deaths among men in the United States. Metastasis plays a major role in patient 
prognosis and treatment options. One of the factors that influences metastasis is the 
activation of the c-Met signaling pathway. Activation of the growth factor c-Met results 
in cytoskeletal rearrangement, migration, and invasion. Previous studies have shown 
CD82 to act as an active metastatic suppressor in normal, healthy cells and is 
downregulated in various forms of cancer. When CD82 is re-expressed in cancer cells, 
the cells no longer express metastatic characteristics. The purpose of this study was to 
determine what effect, if any, re-expression of CD82 in prostate cancer cells had on c-
Met mediated migratory characteristics. METHODS AND MATERIALS: Two prostate 
cancer cell lines were utilized for this project. PC3-29 cells have been engineered with a 
vector that expresses CD82 and PC3-5V carry an empty vector and were used as a 
control in this study. ANALYSES: Expression levels of CD82, c-Met, related migratory 
proteins, and the activation state of c-Met were determined via western blot analysis. 
Visualization of cytoskeletal changes was done by staining F-actin fibers and focal 
adhesions. RESULTS: Re-expression of CD82 in PC3-29 cells led to a decrease in c-Met 
activation. CD82 prevented the formation of F-actin fibers and focal adhesions needed 
for metastasis. CONCLUSIONS: CD82 directly impacts the activation of c-Met by 
preventing the phosphorylation of Rac1, inhibiting the cytoskeletal changes needed for 
metastasis to occur.  
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Chapter One: Introduction 
 
Prostate cancer is the second leading cause of cancer deaths among men in the 
United States (1). The traditional treatments for prostate cancer are castration and 
androgen-ablative therapies (2). Prostate cancer cases can be divided into two categories: 
typical and non-typical. Typical prostate cancer over-expresses androgen receptors and 
prostate specific antigen (PSA). 
Therapeutics for prostate cancer 
have taken advantage of these two 
targets, but, recently research has 
found that the use of androgen-
ablative therapies and related 
chemotherapies can lead to 
resistance in recurrent prostate 
cancer cases (2). Non-typical 
prostate cancer cases do not express 
androgen receptors nor PSA, 
significantly limiting treatment 
options. This expanding need for 
new drug targets for prostate cancer 
treatment has spawned hundreds of 
research studies into this disease.  
The rate at which a malignant tumor begins to spread, or metastasize, has a direct 
impact on patient prognosis. A localized tumor has better treatment options than one that 
Figure 1: Outline of the c-Met signaling pathway. c-Met 
has been shown to have one endogenous ligand, HGF. 
The docking of HGF to the c-Met receptor on the cell 
surface signals a multitude of cellular activities that aid 
in the development of metastatic characteristics. 
Modified from Sridhar and Miranti, 2006. 
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has metastasized to other areas of the body. One of the factors that has been shown to 
lead to metastasis is the activation of the c-Met signaling pathway. The c-Met pathway 
has been implicated in many cellular activities, including metastasis (Figure 1) (3). 
Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. HGF 
has been shown to promote the invasiveness of cancer cells by increasing matrix 
adhesion and encouraging the migration of tumor cells (4). The basement membrane is a 
thin, fibrous barrier separating the endothelium from the connective tissue underneath. 
Once cancer cells have broken through this membrane, they are able to spread to the 
nearest lymph node. The lymphatic system will give the cells direct access to the 
bloodstream. -Met signaling can also be activated by engaging integrins. Integrins allow 
the cell to respond to rapidly changing conditions in the cellular environment. An 
elevation in integrin levels has been associated with tumorgenesis and metastasis (5). 
Activation of c-Met results in the phosphorylation of four separate sites within the cell.  
In addition to integrins, the absence or reduction of tumor suppressor proteins also 
play a major role in the promotion of tumorigenesis. Previous studies have shown the 
tumor suppressor protein CD82 to be an active metastasis suppressor in normal, healthy 
cells (5). The downregulation of CD82 has been confirmed in metastatic tumors, 
indicating that the protein may play a role in the suppression of metastatic signaling (5). 
Cells that express physiological levels of CD82 show an overall decrease in migratory 
behavior (5).  CD82’s ability to interact with c-Met opens an entirely new area of 
research into c-Met and its metastatic signaling cascade. A better understanding of the 
mechanisms behind prostate cancer metastasis would be invaluable to developing new 
treatments for castration-resistant and non-typical prostate cancer.  
12 
 
Incidence, Detection, and Treatment of Prostate Cancer 
 In the year 2013, the most recent data available from the Centers for Disease 
Control and Prevention, a total of 176,450 men were diagnosed with prostate cancer in 
the United States (6). Of those men diagnosed, 27,681 died from prostate cancer in that 
same year (6). The incidence of prostate cancer is steadily rising worldwide, necessitating 
the need for more research into this particular form of malignancy (7).  A better 
understanding of the risk factors and pathology of this disease is important for developing 
better treatments.  
 The risk factors that can lead to an increased chance of developing prostate cancer 
are varied. One of the most important risk factors is age. It is estimated that only 25% of 
prostate cancer cases will be diagnosed before the age of 75. Of all the different types of 
cancer, prostate cancer has been shown to have the steepest age-incidence curve (7). 
There also appears to be a genetic component in prostate cancer cases, as individuals who 
have a first-degree relative diagnosed with the disease have a higher risk of developing 
prostate cancer (7). Other risk factors include exposure to radiation, recurring urinary 
tract infections, and a history of smoking (7).  
 Currently, there are two methods of detecting prostate cancer that have gained 
clinical acceptance: PSA screening and rectal examinations. The 1980’s saw a rise in 
prostate cancer diagnosis as the clinical world was introduced to the prostate-specific 
antigen screening (PSA) (8). PSA is a protein produced in the prostate glands and 
elevated levels of this protein have been linked to the development of prostate cancer. 
PSA has been used to aid in the diagnosis of prostate cancer and patient prognosis 
because of this relationship. Recently, the value of using prostate specific antigen as a 
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method for detecting the presence of cancer has been called into question. The 
development of the PSA screening test in the mid-1980’s led to an increase in the 
reported number of prostate cancer cases; better diagnostic tools generally lead to more 
cases of a disease being discovered. A study conducted in 2002 revealed that, per a 
computer model of incidence rates, approximately 29% of prostate cancer diagnosis 
among white males and 44% among black males were not clinically significant (9). 
Treating low grade prostate cancer with high grade chemotherapy can lead to resistance 
over time.  Research studies conducted among original tissue samples taken from patients 
in the 1980’s revealed that most of the cases diagnosed were not clinically significant, 
highlighting the lack of specificity in PSA screening (9).  
The sensitivity of the PSA screening test can be improved. PSA levels can predict 
patient prognosis in 25% of all differentiated cancers when used in combination with the 
Gleason histological diagnosis method (10). Approximately 50% of the men diagnosed 
with prostate cancer will find that the cancer has metastasized beyond its tissue of origin 
(10). These statistics demonstrate the need for more specific detection methods of 
prostate cancer, which can only be achieved through more intensive research. 
 
Cellular and Molecular Pathology of Prostate Cancer 
Carcinogenesis is the transition of a benign tumor to a malignant one. It is an 
important step in the progression of prostate cancer that has yet to be fully understood. 
Research has provided significant evidence to suggest that carcinogenesis involves major 
genetic changes within the once-healthy tissue, including the activation of oncogenes and 
the loss of tumor suppressor genes (11).  
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 There are three distinct phenotypes currently associated with the transition of 
normal prostate tissue to prostate cancer (11). The first is the secretory luminal cells in 
the prostate epithelial tissue beginning to express prostate specific antigen (PSA), as well 
as cytokeratins 8 and 18 (12, 13, 14, 15). PSA is a serine protease produced by prostate 
epithelial cells and its production is regulated by the male hormone androgen (8). The 
second most important phenotype is that the basal cells, which function to connect the 
epithelial tissue to the stroma, begin to express cytokeratins with high molecular weights 
(12) (8). Cytokeratins are proteins made up of keratin filaments found in the 
cytoskeletons of epithelial cells (13). The final phenotype is when the neuroendocrine 
cells, responsible for secreting products that may promote cell growth, begin to 
differentiate (8). The development of these phenotypes result in a decline in cellular 
division in the basal cell layer and an increase in the proliferation of the luminal secretory 
cells (8). These changes that occur prior to a cell acquiring a diseased phenotype are 
referred to as “premalignant proliferation disorders” and have been associated with the 
abnormal expression of both tumor suppressor genes and oncogenes (8). 
 
Genetic Factors Influencing Metastatic Characteristics  
Metastasis is possibly the deadliest characteristic that a malignant tumor can 
acquire. Once a tumor has penetrated the barrier that separates the tissue from the blood 
supply, the cancer is free to travel throughout the entire body. It is imperative that more 
research efforts into better understanding the mechanisms behind the transition to cancer 
cells and the conversion of a primary tumor to a metastatic one. As mentioned before, the 
metastatic status of prostate cancer plays a major role in patient prognosis, as well as in 
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the selection of an appropriate treatment method. The metastatic status of the cancer 
hinders treatment efficacy.  
Cancer is a condition in which cell populations disregard mitotic signaling and 
rapidly begin to divide. Within a cell’s genetic code are the instructions for cellular 
division, for which there are checkpoints a cell must meet before it divides by a process 
known as mitosis. These checkpoints ensure that the cell has doubled all genetic material, 
organelles, and other cellular resources so the process of mitosis results in two complete, 
healthy cells. When a cell transitions into a cancerous cell it begins to reproduce at such a 
rate as to outcompete all the normal cells in the surrounding tissue. The accumulation of 
these cancerous cells in one place leads to the development of a malignant tumor. The 
scientific community now recognizes that cancer arises when there are mutations in one 
of two sets of genes: proto-oncogenes and tumor suppressors. Proto-oncogenes are genes 
that have the potential to protect cells from apoptosis, or controlled cell death. Alterations 
in proto-oncogenes that lead to their activation include gene amplification, 
overexpression, and other types of mutations (14). Tumor suppressors genes prevent 
tumor formation. These genes become inactive when a mutation occurs in both alleles 
(14).  CD82 is a tumor suppressor that has been demonstrated to be downregulated in 
prostate cancer (5).  
Growth factor receptors also aid in the development of metastatic characteristics 
in advanced cancers. Similar to proto-oncogenes, these receptors are responsible for 
regulating cell growth and division. The overexpression of growth factor receptors has 
been observed in multiple types of cancer, including prostate cancer. c-Met is a growth 
factor receptor that has been demonstrated to have an impact in the transition from a 
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localized tumor cell to a metastatic tumor. The study described in this manuscript had the 
goal of determining the way in which the tumor suppressor CD82 interacts with the cell 
signaling mediated cascade by the growth factor receptor known as c-Met.  
 
Progression from Localized Tumor to Bone Metastasis in Prostate Cancer 
 The degree to which a prostate cancer tumor has metastasized is directly 
proportional to the expected survival rate of that patient. Patients with a localized tumor 
have a five-year survival rate of approximately 100%; for those with a metastatic 
phenotype, the five-year survival rate can drop to as low as 31% (15). While prostate 
cancer is able to metastasize to any other tissue type in the body, it demonstrates a 
proclivity towards invading the bone (15). The location of the prostate gland in the male 
pelvic region provides an environment rich in bone to metastasize to. One of the 
hallmarks of prostate cancer development is its dependence on stimulation via the 
secretion of androgen. Androgen binds to the receptor found in the cytoplasm; upon 
activation, the receptor will then translocate into the nucleus (15). Once the complex has 
entered the nucleus, it will go on to influence the transcription of androgen-related genes 
and the proliferation of the prostate cancer cells (15).  
 The dependence of prostate cancer on the secretion of androgen has led to 
castration serving as the most common treatment option (15). While surgical castration 
can be performed, chemical castration is a temporary alternative; patients are treated with 
antiandrogen drugs that function to either prevent androgen from being secreted or 
prevent androgen from binding to its receptor. The effectiveness of castration on early 
metastatic prostate cancer is limited, as the disease will eventually adapt to the new 
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chemical environment and become “castration resistant” (15). One hypothesis behind this 
phenomenon is that the tumor gradually becomes hypersensitive to androgen stimulation, 
lowering the stimulation threshold so that it will take less androgen to elicit the same 
initial response (15). Another possibility is that the tumor adapts in such a way that both 
the autocrine and paracrine production of androgen is upregulated in order to compensate 
for the effects of castration (15). The androgen receptor could also be adapting to the lack 
of androgen by becoming activated via other steroids, such as estrogens, and ligand-
independent activation by tyrosine kinases (15).  
 The metastasis of prostate cancer is a complex, multistep process in which a 
tumor cell will leave its tissue of origin and spread to a secondary tumor site (15). The 
first step of the metastatic process is decreased cell adhesion, which is characterized by a 
shift from epithelial to mesenchymal tissue (15). This phenomenon is known as the 
epithelial to mesenchymal transition (EMT), and is when epithelial cells begin to take on 
the properties of mesenchymal stem cells. While EMT has yet to be fully understood, one 
of the hallmark traits is cadherin switching (15). Normal epithelial cells express a large 
amount of E-cadherin. During cadherin switching, the production of E-cadherin is 
downregulated, and expression of N-cadherin is upregulated to levels normally associated 
with mesenchymal stem cells (15). There is also an association between decreased E-
cadherin expression and decreased β-cadherin expression, both of which have been linked 
to more aggressive cases of prostate cancer (15). In vitro model system studies have 
proven that the levels of E-cadherin are significantly reduced in more invasive human 
prostate cancer cell lines (15). 
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When a cell has undergone EMT, there is a noticeable decrease in cell adhesion 
that is observed. The second step in metastasis is the cells demonstrating mesenchymal 
properties begin to detach from the primary tumor site. It is critical that normal cells 
become anchored to their environment, as forming cell junctions with adjacent cells is 
needed for adequate cell-to-cell communication. For cancer cells, the dependence on 
physical stability is not as crucial. Normal prostate epithelial cells are limited in their 
ability to migrate, as the basal layer of cells is attached to the lumen, which in turn is 
attached to the basement membrane (15). Metastasis is characterized by decreased cell 
adhesion; early metastatic prostate cancer cells have been shown to have altered 
expression of molecules that are critical to cell adhesion, such as E-cadherin (15). E-
cadherin is a cell adhesion molecule (CAM) that serves to form an anchor between cells 
and also works with β-cadherin to hold the actin cytoskeleton in place (15).  
 Integrins also play a role in the decreased cell attachment observed in the initial 
stages of metastatic prostate cancer. These signaling molecules are responsible for 
regulating cellular processes such as cell survival, cell motility, and cell migration by 
associating with focal adhesions (15). The principle integrins found in normal prostate 
epithelial cells are α5β1, α6β1, and α6β4, along with slightly lower expression of αvβ3 
and α3β1 (15). There is a correlation between the reduced expression of α6 and the 
invasiveness of prostate tumor biopsy samples that has been experimentally demonstrated 
(15). The reduced expression of these critical integrins results in a decrease in cell 
adhesion which further stimulates metastasis in malignant tumors (15).   
 Signaling through focal adhesions, (macromolecular assemblies that transmit 
regulatory signals), can also be accomplished by nonreceptor tyrosine kinase focal 
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adhesion kinase (FAK) and the Src family of kinases (15). When a cell is preparing to 
migrate, focal adhesions are assembled at the edges of the cell and form structures that 
are known as lamellipodia, allowing the cell to anchor itself to the extracellular matrix 
(ECM) to pull itself along the tissue. Once the cell has finished contacting, the focal 
adhesions will disassemble and then re-form for the next movement (15). Studies have 
shown that the inhibition of FAK has a significant effect on a cell’s ability to migrate, 
including changes in integrin concentrations (15). PC3 cells a correlation between high 
levels of FAK expression and an increase in the development of metastatic characteristics 
(15). After integrins associate with FAK, the phosphorylation of FAK leads to the 
phosphorylation of Src (15). The Src family of kinases stimulates cell migration via the 
phosphorylation of the E-cadherin/β-cadherin complex (Figure 2). The Src family of 
kinases has been shown to be activated by several different mechanisms, including the 
growth factor receptors. Phosphoinositide 3-kinase (P13K) is part of a family of signal 
transduction enzymes that is responsible for activating β-catenin.  
Prostate cancer cells can migrate in part due to the partial degradation of the ECM 
by molecules known as proteinases (15). The major proteinases that are involved in the 
degradation process associated with the migration of prostate cancer cells are matrix 
metalloproteinases (MMPs) and serine proteinases (15). MMPs are a family of 
proenzymes that bind to zinc and remain activated until proteolytic cleavage occurs (15). 
ProMMP-2 is activated by Type 1 MMP, which then activates MMP-2 and MMP-9 (15). 
Compared to normal levels found in prostate epithelial cells, metastatic prostate cancer 
cells have a higher ratio of MMP-2/-9 to tissue inhibitor of metalloproteinases-1 (TIMP-
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1) (15). Similar elevated ratios have been correlated with higher scoring tumors on the 
Gleason scale, and thus is also associated with a higher patient fatality rate (15).  
When the ECM has finally degraded sufficiently to allow the malignant cells to 
infiltrate the circulatory system, they must remain in circulation long enough to attach to 
the vascular endothelium (15). The prostate cancer cells must then interact with the 
surrounding tissue to leave the blood vessel and enter the bone, which is one of the most 
poorly understood aspects of prostate cancer metastasis (15). As mentioned before, 
prostate cancer displays a high affinity for metastasizing to bone tissue (15). One aspect 
of the binding of metastatic prostate cancer to the bone is that the endothelial tissue 
within the bone is constitutively expressing adhesion molecules, such as P-selectin (15). 
P-selectin is a transmembrane protein that is commonly expressed in both endothelial 
tissue and platelets. Specifically, it is found in Weibel-Palade bodies in endothelial tissue 
and in the alpha granules in platelets (16). When the appropriate cells are stimulated, P-
selectin is translocated to the plasma membrane (16).  
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Somatic Mutations Contributing to the Metastatic Phenotype in Castration 
Resistant Prostate Cancer 
 Molecular biomarkers are objective characteristics that indicate a diseased 
phenotype, even if the patient is not yet presenting symptoms. In terms of prostate cancer, 
molecular biomarkers would improve patient prognosis by providing physicians with the 
means of distinguishing between aggressive subtypes and identifying metastasis early on. 
A twin study published in 2009 estimates that approximately 42% of disease disparity 
can be linked to genetic variation, some of which are linked to somatic alterations (17).  
Insufficient data regarding a metastatic phenotype is partially due to the heterogeneity of 
primary prostate tumors (18). Prostate cancer tumors are often made up of many 
Figure 2: Graphical representation of the Src stimulation of metastatic invasion via the phosphorylation of the E-
cadherin/β-catenin complex. When the E-cadherin molecule is phosphorylated, it forms a complex with β-
catenin. The Src protein is then activated, and the complex is able to interact with the actin cytoskeleton. Adapted 
from Jin, et al. (2011) (15) 
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genetically distinct layers that make it difficult to identify the actual mutations that led to 
the cancer cells migrating from their tissue of origin.  
 There is also substantial evidence to support the association between somatic 
mutations and the development of hormone-related cancers. One of the most well-known 
associations is between specific mutations in the BRCA1 and BRCA2 genes and the 
development of breast cancer. A study published in 2013 found that exomes of metastatic 
prostate cancer tumors contained an Ashkenazi Jewish germline mutation del185AG in 
BRCA1 (18). The BRCA1 gene is located on the seventeenth chromosome; the germline 
mutation del185AG indicates a 185 deletion of AG (19). Specifically the BRCA1 gene is 
responsible for the regulation of the cell cycle and DNA repair (19). In addition to the 
del185AG germline mutation, researchers found sixty-two somatic alterations in proteins, 
some of which were products of cancer related genes (18). The cancer related genes 
found to have genetic variants amongst the prostate cancer tumor samples were 
TMPRSS2-ERG, TET2, and PBRM1 (18). The majority of the alterations were present in 
only the metastatic prostate cancer tumor samples, with a smaller group of alterations 
being specific to primary tumors only (18).  
 
CD82/KAI1 Protein as a Metastasis/Tumor Suppressor 
 The metastatic suppressor CD82 was first characterized by Dong, et al. in 1995 
(20). Microcell-mediated chromosome transfer revealed the location of the gene to be 
11p11.2-13 and was later confirmed using Southern blot analysis (20). The four-domain 
structure of CD82 places it in the tetraspanin superfamily (21). Tetraspanins have been 
found only in multi-cellular organisms and are expressed at relatively similar levels in all 
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organisms in which they are present (21). While CD82 does not appear to have any 
function by itself, it has been found to associate with other proteins and regulate their 
functions. The down-regulation of CD82 has been linked to tumor metastasis and poor 
patient prognosis. Studies have shown that the loss of CD82 expression has been 
implicated in approximately 70% of all prostate cancer cases (7). 
 One of the mechanisms by which CD82 controls metastasis is by influencing 
cellular adhesion. A study published in 2015 demonstrated that the expression levels of 
CD82 play a role in inhibiting both metastasis and invasion in primary tumor cells (22). 
When malignant tumor cells were modified to over-express CD82, researchers found that 
the cells over-expressing the CD82 protein adhered more strongly to the endogenous 
matrix, and the ability of the cells to adhere to the endothelium tissue of blood vessels 
was greatly diminished (22). The over-expression of CD82 inhibits a tumor cell’s ability 
to invade other tissues by influencing cellular adherence to the tissue of origin (22). This 
means that when CD82 is over-expressed in tumor cells they are firmly adhered to the 
surrounding tissue, and the probability of the tumor metastasizing is very low. CD82 
expression is up-regulated by the cellular tumor antigen p53, the proto-oncogene junB, 
and the transcription factor known as AP2 (5). The over-expression of CD82 also 
prevents tumor cells from adhering to the walls of blood vessels. It should be noted here 
that while CD82 does inhibit tumor metastasis, it does not interfere with primary tumor 
formation (5). CD82 interferes with a primary tumor’s ability to invade and migrate to 
non-native tissues (5). What is currently not known is the mechanism by which CD82 can 
suppress tumor cell invasion and metastasis.  
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Regulation of Growth Factor Receptor c-Met by CD82 
 CD82 regulates cellular activities by associating with proteins from its location in 
the cellular membrane. One of the proteins that CD82 has been found to associate with 
the growth factor receptor known as c-Met (23). Growth factors are proteins that are 
responsible for maintaining the growth and development of cells by regulating intra-
cellular activity via a biological phenomenon known as a signaling cascade. c-Met is a 
growth factor receptor that is found within the cellular membrane in all cells, whether it 
be cancerous or healthy. The only known ligand that binds to c-Met is hepatocyte growth 
factor (HGF). When HGF docks at the binding site located on the α subunit of the c-Met 
protein, the protein is activated. Activation of the c-Met protein results in the 
phosphorylation of four key sites: pY1003, pY1234/1235, pY1349, and pY1356. The 
phosphorylation of these sites recruits specific downstream molecules that lead to 
downstream signaling events, such as cell survival, cell proliferation, cytoskeletal 
rearrangement, cell adhesion, invasion, and migration (Figure 1).  
The c-Met receptor can also be activated by integrin crosstalk within the 
cytoplasm. Integrins are small signaling molecules that facilitate a connection between 
the extracellular matrix and intra-cellular structures, such as the cytoskeleton (23). The 
interaction between integrins results in the phosphorylation of the c-Met phosphorylation 
sites and the signaling cascade begins. Several studies have reported a change in integrin 
levels within cancerous tissues, with prostate cancer cells showing elevated levels of 
α3β1 and α6β1 (23). These integrins have been shown to regulate the same cellular 
activities as c-Met, further implicating them in regulating cell migration and metastasis 
(5). 
25 
 
 Research into c-Met has yet to reveal the specific ways in which CD82 interferes 
with the c-Met signaling cascade and its related downstream molecules. An experiment 
conducted by Sridhar and Miranti in 2006 provided significant insight into the regulatory 
action of CD82 on the c-Met signaling pathway. Using the prostate cancer cell line PC3, 
researchers performed a series of experiments to test the hypothesis that CD82 regulates 
the integrin-mediated activation of the c-Met pathway (5). They chose a metastatic 
prostate cancer model, as c-Met has been shown to be highly over-expressed in prostate 
cancer and has been linked to chemotherapy resistance. One of the study’s major findings 
was that CD82 does not regulate the actual expression of c-Met. After CD82 was re-
introduced into the metastatic prostate cancer cells, western blots showed that there was 
the same concentration of c-Met protein in both the experimental cells and the controls 
(5). However, when the activation levels of c-Met were tested, there was a definite 
difference between the two cell lines. The cells that were expressing CD82 showed 
markedly reduced levels of activated c-Met, while the levels of activated c-Met in control 
cells remained high (5). Even though c-Met is still being produced at the same rate within 
the cancerous tissues, the re-expression of CD82 appears to prevent c-Met from being 
activated (5).  
Having concluded that CD82 expression was interfering with the activation of the 
c-Met signaling pathway, the next step was to investigate the mode of inhibition. The first 
hypothesis was that CD82 and c-Met were physically interacting with one another due to 
their respective locations on the cell surface. When immunostaining was carried out on 
CD82-expressing cells, it was discovered that this was not the case. While CD82 and c-
Met are located near one another, there is no co-localization between the two proteins 
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that would result in the de-activation of c-Met (5). This further supported the authors’ 
hypothesis that CD82 was interfering with the integrin crosstalk responsible for c-Met 
activation within the cytoplasm.  
 After immunostaining ruled out the possibility of co-localization between the two 
proteins, the authors then tested the hypothesis of an indirect deactivation mechanism. c-
Met is responsible for the regulation of many cellular activities and it does so by the 
activation of downstream signaling molecules. One of these molecules is Src, a non-
receptor kinase that is known to transform healthy cells into malignant tumors when 
overexpressed (24). When HGF binds to c-Met, or c-Met is activated by integrin 
crosstalk, the phosphorylation of pY1349 leads to the activation of Src (23). Higher 
expression of Src and its downstream signaling partners have been demonstrated to be 
overexpressed in a variety of cancers, including breast cancer, pancreatic cancer, and 
prostate cancer (24). In the c-Met signaling pathway, Src substrates include focal 
adhesion kinase (FAK) and p130 Crk associated substrate (p130Cas). Fibroblasts from 
FAK-null mice demonstrate decreased migration behavior, but an increase in local 
adhesions to the surrounding cytoskeleton (25). Migration and invasion of tumor cells 
require an elaborate rearrangement of the cytoskeleton to form the lamellipodi (a 
cytoskeletal projection made of actin filaments), necessary for cell movement. The 
construction and maintenance of this actin fiber scaffolding is carried out through the 
formation of focal adhesions, a task in which FAK plays a critical role. The FAK-Src 
complex is then responsible for the phosphorylation of paxillin, and p130Cas (25). Both 
molecules mediate the organization of focal adhesions and the cytoskeleton, which 
ultimately allow the cell to migrate (25). Similar to the FAK-null mice, mice lacking 
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p130Cas demonstrated poor actin filament arrangement and decreased migration 
behavior (25). 
 Given the similarities between FAK-null mice and PC3 cells re-expressing CD82, 
the possibility that CD82 was interfering with Src activation was explored. Using 
western-blotting analysis, CD82 was found to regulate the phosphorylation of Src and 
subsequently the activation of FAK and p130Cas (24). The presence of the CD82 protein 
was linked to the inhibition of the tyrosine phosphorylation associated with p130Cas 
(24). When CD82 is present, there is a reduction in the integrin mediated activation of 
Src and related proteins, most likely contributing to the lack of migration seen in CD82 
expressing tumors. Keeping in mind that the inhibition of c-Met also blocks invasion, the 
conclusion can be reached that CD82 expression reduces the invasive phenotype through 
the reduction of both c-Met and Src signaling (24).  
 
Oncogenic c-Met Signaling and Tumor Development  
The identification of c-Met as an oncogenic target originated from the discovery 
of a missense c-Met mutation in patients who had been diagnosed with hereditary 
papillary renal cell carcinomas (PRCCs) (26). These mutations include trisomy of 
chromosome 7, which has been identified as a common mutation in PRCC patients (27) 
(28). Somatic mutations of c-Met have been identified in a variety of cancers, including 
gastric, head and neck, liver, ovarian, and thyroid (29). Elevated levels of the c-Met 
ligand HGF lead to the over-activation of the c-Met signaling pathway. In addition to 
somatic mutations in c-Met being linked to cancer development, somatic mutations in 
HGF have also been identified in a variety of different cancers (29). One of the most 
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common mutations in HGF is in the promoter region of the HGF gene, resulting in the 
increased expression of HGF and the over-activation of the c-Met pathway (30). A study 
conducted by Ma et al. in 2008 successfully provided a direct link between the 
dysregulation of c-Met signaling and the development of tumors in human patients (31).  
The degradation of the extracellular matrix (ECM) surrounding the tumor cell is a 
major milestone on the road to metastasis (32). Tumor cells are capable of releasing 
enzymes known as proteases that are capable of hydrolyzing peptide bonds in order to 
break down the ECM (32). Also crucial to the metastasis of cancer is the formation of 
invadopodia within the cytosol (32). Similar to lamellipodia, invadopodia are actin-rich 
cytoskeletal structures that are mediated by intracellular components such as focal 
adhesion kinase (FAK), paxillin, cdc42 and Rac1 (32). cdc42 and Rac1 are both members 
of the Rho GTPase family, which has been shown to promote the formation of 
lamellipodia and invadopodia (32). Rac1 is required for the formation of cell protrusions 
in both collectively and individually migrating cells (33). To degrade the ECM and 
invade new tissue, tumor cells must coordinate their actions with one another. Cell-to-cell 
communication is crucial to the development of invadopodia and lamellipodia by 
restricting the formation of protrusions to the leading cell (33). A lack of this 
communication between cells results in a chaotic disorganization that hinders the tumor 
cells’ ability to organize their cytoskeletons to complement one another (33). cdc42 plays 
a major role in the cell-to-cell communication associated with the collective movement of 
migrating cancer cells (33). The c-Met signaling pathway stimulates the activation of the 
Ras pathway. The subsequent activation of Rac1/Rho/cdc42 leads to the reorganization of 
the cytoskeleton needed to form cellular structures needed for invasion and migration.   
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c-Met Activation of Rac1/Rho/cdc42 Necessary for Cell Migration 
More recent studies have supported the hypothesis that CD82 is interfering with 
the integrin crosstalk responsible for the C-Met signaling pathway, but they have yet to 
identify the exact point in the pathway that CD82 is targeting. The re-expression of CD82 
does not alter the activation of ERK (extracellular signal-regulated kinase), or AKT 
(RAC-alpha serine/threonine-protein kinase), which narrows down the list of possible 
targets for CD82 (24). The specific target this publication focuses on is the 
Rac1/Rho/cdc42 pathway. When the c-Met signaling cascade begins, growth factor 
receptor-bound protein 2 (Grb2) forms a complex with son of sevenless (SOS). After the 
complex has forms, the next step is the activation of Ras, which in turn activates the 
Rac1/Rho/cdc42 step. The end result of the activation of these proteins is actin 
cytoskeleton arrangement and changes in cell motility. Rac1 is a small GTPase that is 
involved in cell migration, cell cycle progression, and cytoskeleton arrangement (34). 
Specifically, Rac1 aids in the formation of lamellipodia and membrane ruffling (34). 
Lamellipodia formation can be is the first step in the cytoskeletal rearrangement required 
for migration; the actin fibers within the cell begin to extend through the cell lamella 
region, which is near the front of mobile cells (34). 
 
Metastatic Signaling by c-Met via Rac1 Activation  
 As mentioned previously, the Rho-family of GTPases has been shown to promote 
metastatic growth via cytoskeleton dynamics and cell motility (35). These cellular 
activities are tied together with the growth receptor c-Met, the deregulation of which has 
been linked to the development of melanoma in mice models (36). The advancement of 
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tumors into a metastatic stage is made possible not only through c-Met, but the complex 
network of effector molecules that connect c-Met to the cellular controls for migration, 
invasion, and cytoskeleton dynamics (37) (26). This signaling network only functions 
through the association of c-Met with repulsive co-receptors (plexins), adhesion 
molecules such as the α6β4 integrin, and the coordinated actions of the Rho family 
GTPases Rac1, Rho, and cdc42 (38) (39) (40).  
 Recently, a new concept regarding signal transduction maintained by growth 
factor receptors has begun to appear in literature. Specifically, there is growing evidence 
to suggest that receptors, as well as the adhesion molecules they communicate with, rely 
on reactive oxygen species (ROS) and hydrogen peroxide H2O2 as critical intermediate 
molecules in the downstream cascade (41) (42). In addition to cytochromes, Rac1 has 
been shown to be an important molecular piece of the oxidase complex found in 
mammalian cells (43). The Rac1/ROS interaction has been demonstrated to play a role in 
mitogenic signaling by PDGF and by oncogenic H-Ras (44) (45) (46). The Rac1/ROS 
signaling complex is activated by integrins upon cellular adhesion to the ECM, and is 
necessary for the development of proper focal adhesion assembly in NIH-3T3 cells (47) 
(48). It is reasonable to assume that the oxidant intermediates generated by Rac1 are 
responsible for the metastatic characteristics seen in prostate cancer (49).  
The connection between Rho GTPases and the cytoskeleton has been extensively 
studied in the neuroblastoma line N1E-115. The activation of Rac1 and cdc42 in these 
cells results in the formation of lamellipodia and filopodia along the very edges of the 
neurite (50). Despite differences in cell types, the biochemical processes behind the 
lamellipodia and filopodia formation rely on the activation of Rho GTPases in to form the 
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actin filaments necessary for migration and invasion (50) (51). This relationship carries 
over to fibroblasts, neurons, and macrophages (52). The effect of Rho GTPase activation 
on the actin cytoskeleton can be observed in epithelial and endothelial tissue, as well as in 
circulating cells such as lymphocytes, mast cells, and platelets (53) (54) (55). The effects 
of Rho GTPase activation is not limited to rearranging already-present actin filaments; 
studies have shown that Rho GTPases, Rac1 plays important regulatory role in 
coordinating the cellular activities that rely on the dissembling and re-assembling of actin 
fibers (56). Rho activation and signaling is required to form and maintain focal 
adhesions, and integrin complexes propagate the movement of the cytoskeleton (57) (58). 
With keratinocytes, it has been discovered that both Rac1 and Rho activation are required 
for the assembly of the actin cytoskeleton (59).  
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Purpose 
 The focus of this research project was to identify the specific phosphorylation 
site(s) and the subsequent signaling pathways in c-Met regulated by CD82. To identify 
the specific pathways and to determine the overall role of CD82 in prostate cancer 
metastasis, the following objectives were addressed: 
1. Identify the c-Met phosphorylation site being blocked by CD82 expression 
a. Integrins within the cells were engaged by plating the cells onto a 
substrate of collagen or laminin. The cells were then lysed, and the levels 
of phosphorylated Met, along with the specific Met phosphorylation sites 
(PTyr 1234/1235 and Total Ptyr), were analyzed by gel electrophoresis 
and western blot.  
2. Determine whether the Rac1 pathway is being regulated by CD82 expression 
a. Integrins within the cells were engaged via an adhesion assay. The cells 
were then lysed, and the levels of both Rac1 and cdc42 were analyzed by 
gel electrophoresis and western blot.  
3. Identify the Rac1 induced cellular changes that are being affected by CD82 
expression: invasion, migration, adhesion, lamellipodia formation, and F-actin 
fiber arrangement. 
a. The cells were fixed to a coverslip coated with either collagen or laminin, 
and then stained to visualize F-actin fibers and focal adhesions 
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Chapter Two: Materials and Methods 
Cell Lines and Cell Culture 
 Human prostate cancer cells (PC3) were obtained from Dr. Cindy Miranti of the 
University of Arizona. From this parental cell line, three clones were generated: PC3-5V, 
(containing an empty vector), as well as PC3-29 and PC3-#1, both of which express 
CD82. The cells were cultured in F12K Media, (Gibco), which was supplemented with 
fetal bovine serum (FBS), streptomycin, penicillin, glutamate, and amphotericin B. The 
cells were plated in 10mL sterile flasks and kept in an incubator at 37ᵒC with 5% CO2. 
Cells not currently being used were flash frozen in liquid nitrogen and stored at -80ᵒC 
until they were needed. Frozen cells were quickly thawed in a 37ᵒC water bath, and then 
added to a sterile flask with F12K Media (Gibco) at the same temperature. The cells were 
then cultured until the flasks were 70-80% confluent, after which further experiments 
were performed.  
 
Adhesion Assay 
 Each cell line was grown until flasks showed 70-80% confluency. Thereafter, the 
media was switched to serum-free media, (Gibco, RPMI Medium 1640, Product 
No.11875-093), and the cells were grown in this starvation media for an additional 24 
hours before beginning the procedure. Substrate plates were also prepared 24 hours in 
advance of the procedure. A working stock of 10µg was made of the desired substrate 
stock, (1.0 mg/mL laminin or 2.3 mg/mL collagen), and then added to sterile 10mL flasks 
in an even layer. Plates were then kept at 4ᵒC overnight. The following day, the 
remaining substrate was removed via aspiration, and the plates were washed two times 
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with PBS. Once the washes were complete, 1% BSA-PBS solution was added evenly to 
each plate. The coated plates were allowed to incubate at 37ᵒC for at least 1 hour. 
Approximately 15 minutes into the incubation period of the cells, the BSA solution was 
removed and the substrate plates were washed with PBS. The substrate plates were then 
incubated upside down to dry until the cells were ready. 
 For the preparation of the cultured cells, the plates were removed from the 
incubator and washed with PBS buffer two times. Once all the PBS had been aspirated, a 
1:4 solution of 2X trypsin-EDTA was added to the plates. The plates were allowed to 
incubate at 37ᵒC for 10-15 minutes in the 2X trypsin-EDTA solution, or until the majority 
of the cells had dislodged. A solution of PBS-EDTA/STI was added to each of the plates 
to stop trypsinization. Each cell line was separately pooled into a centrifuge tube and the 
plates were washed twice more with the same solution (PBS-EDTA-STI) and pooled 
together. The supernatant was discard after centrifugation at 800 rpm for 8 minutes and 
the pellet was re-suspended in PBS-EDTA/STI and re-centrifuged. The supernatant was 
again removed and the cells resuspended in (without phenol red) DMEM media (Gibco, 
DMEM high glucose, Product No.31053-028). The tubes, with caps loosened, were 
placed in the 37ᵒC incubator for 30-40 minutes. When the incubation period was 
complete, the cells were added to the substrate plates. The plates were incubated at 37ᵒC, 
checking every 15 minutes for adhesion under a microscope. Meanwhile, the cell 
suspension was centrifuged and the supernatant removed. Lysis buffer (RIPA or MAPK) 
was added and the plates were kept on ice for 30 minutes. Once all of the plates 
developed signs of cell adhesion (actin projections, flattened appearance, etc.), the plates 
were removed from the incubator and carefully aspirated to remove any free-floating 
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cells. The same lysis buffer added to the suspension was also added to the substrate 
plates. After adding the lysis buffer, the plates were immediately placed on ice until all 
plates had been coated in the buffer. For the lysis to take place, the plates were placed at 
4ᵒC for at least 30 minutes. After the lysis had taken place, the cells were removed using 
a cell scraper and then transferred to a microfuge tube. The samples were centrifuged, 
including the cell suspensions, at maximum speed for 5 minutes at 4ᵒC. Once the samples 
had been collected, a BCA protein assay (ThermoFisher Scientific, Catalog No. 23225) 
was performed to determine the concentration of protein in each of the samples. All 
unused samples were stored at -80ᵒC. 
 
BCA Protein Assay 
 On the day of the immunoprecipitation assay, all samples were removed from the 
-80ᵒC environment. The samples were centrifuged at maximum speed for two minutes at 
4ᵒC. Keeping all reagents and samples on ice, a protein assay was performed using the 
PierceTM BCA Protein Assay Kit (ThermoFisher Scientific, Catalog No. 23225). Protein 
standards were prepared using the BCA protein solution provided in the kit. Exactly 
10µL of each sample was added to 40µL of distilled water; 1mL of the mixed Reagent A 
and Reagent B was added after the samples had been thoroughly mixed. The solution was 
also added to the protein standards. The samples and standards were incubated in a 37ᵒC 
water bath for 30 minutes. After the incubation period was complete, the absorbance of 
each sample was measured at 562 nm. This calculation allowed for the concentration of 
protein to be determined in each of the samples.  
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Immunoprecipitation Assay 
 Protein A-agarose beads (Pierce, Product No.20333), were prepared by washing 
the beads three times with 1% BSA in lysis buffer. In between the washes, the beads were 
placed in the centrifuge and spun at max speed for two minutes at 4ᵒC. The cell samples 
were thawed and prepared for the assay by making a concentration of 1 ug/uL in the same 
lysis buffer as used above, then stored on ice until the primary antibody was added. After 
the primary antibody was added, the samples were left on the rotator at 4ᵒC overnight. 
The beads were then washed three times with the lysis buffer, spinning at 4ᵒC for two 
minutes in between each wash. The supernatant was then removed and the beads 
resuspended in 2X SDS buffer (800 uL of 2X sample buffer and 200 uL of beta-
mercaptoethanol). The samples were boiled for five minutes, and then spun for two 
minutes at maximum speed at room temperature. The supernatant was then removed and 
added onto an SDS-gel (sodium dodecyl sulfate with distilled water ) and the proteins 
separated by electrophoresis. 
 
 
Table 1: Targets for immunostaining are given with their corresponding antibody, as well as the 
dilution that was used to achieve optimal results.  
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Western blots 
 A polyacrylamide gel was loaded with equal concentrations of protein for each of 
the desired samples. In addition to each of the samples, a prestained molecular weight 
marker (Novex Benchmark ™ Prestained Protein Ladder, Product No.10748-010) was 
loaded as well. SDS running buffer was added to the gel apparatus prior to the loading 
and running of the gel. The gel was run at 125V for 90 minutes, or until the samples had 
migrated ¾ of the length of the gel.  
 Once the gel had been run to completion, it was then blotted to a PVDF 
(polyvinylidene fluoride) membrane (Immobilon Transfer Membrane, Product No. 
IPFL07810). This was accomplished by placing the electrophoresis gel into a transfer 
tank for 3 hours at 25V using blot transfer buffer. The transfer buffer used for western 
blotting was Novex Tris-Glycine Transfer (ThermoFisher Scientific, Catalog No. 
LC3675) buffer plus methanol, and distilled water. When the gel had been blotted, any 
potential non-specific binding sites were blocked with 5% BSA/TBST and incubated for 
2 hours at room temperature. The appropriate primary antibody was added to the blotting 
membrane (see Table 3), then incubated at room temperature for 2 hours. The blot was 
then washed four times with wash buffer (.1% PBS-2.0 Tween), spending 10 minutes on 
the shaker between each wash. After the final wash, the secondary antibody, (Li-Cor 
IRDye 800CW; donkey-anti-mouse Product No. 926-32212, or donkey-anti-rabbit 
Product No.926-32213), was then added to the membrane, which was allowed to rotate 
for one hour. The blot was again washed four times with the wash buffer, shaking 10 
minutes in between each wash. The blot was illuminated at 800nm and imaged was 
captured using the Li-Cor Odyssey Imaging Suite (LI-COR Biosciences, Lincoln NE).  In 
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the case of fixed cells, an adhesion assay was carried out on an endogenous matrix of 
either collagen or laminin. Once the cells were fixed and permeabilized they were stained 
for the appropriate targets. 
 
Immunostaining 
 In order to carry out the immunostaining necessary to view cytoskeletal 
components, a “mini” adhesion assay must first be carried out. Rather than transferring 
the starved cells to plates that have been coated in collagen, cover slips must be prepared 
instead to visualize the cytoskeleton. Single cover slips were placed in a six well plate, 
and washed three times with 70% ethanol, followed by washing three times with PBS. 
After being coated with a 10µg solution of collagen, the cover slips were allowed to 
incubate at 4ᵒC overnight. On the day of the assay, the cover slips were washed twice 
with PBS and then blocked with a 1% BSA in PBS. The plates containing the starvation 
media and the cells were prepared according to the adhesion assay protocol up until the 
point at which they were added to the collagen coated plates. The cover slips were 
washed two times with PBS, and then kept at 37ᵒC for five minutes to dry. Once the cells 
had been allowed to incubate for roughly 30-40 minutes in clear DMEM medium, 
approximately 1mL of cell suspension was added to each of the cover slips. The 
coverslips were then placed in the incubator at 37ᵒC until adhesion was observed, 
approximately for one hour. Cells were fixed with 2% paraformaldehyde for 20 minutes 
at room temperature. The fixed cells were washed three times with PBS. Once the 
remaining PBS had been removed, the cells were permeabalized with 0.1% Triton in PBS 
and left at room temperature for three to five minutes. The permeabilized cells were then 
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washed three to four times in PBS. The slides were blocked with 0.1% BSA in PBS for 
two hours at room temperature, after which they were washed three times with PBS. The 
cover slips were then carefully transferred from the six-well plates to a plastic tray lined 
with parafilm. Table 4 shows the immunostaining targets with their appropriate primary 
and secondary antibodies with the correct dilution in PBS with 1% BSA and incubation 
period. Before the addition of each antibody, cells were washed three times with 0.1% 
BSA, 0.05% Tween 20 in PBS. The washes lasted approximately 10 minutes each. After 
the secondary antibody had been washed off, the cover slips were once again washed 
three times with 18 MΏ water and carefully dried. A drop of anti-fade reagent 
(ThermoFisher Scientific, ProLong Antifade Reagent, Product No. P36930) was added to 
each slide and the cover slip was inverted on top of it. The slides and cover slips were 
sealed together using clear nail polish and stored in a dark environment at 4ᵒC overnight. 
 Images of the slides were captured using the Olympus BX51 Upright Compound 
Microscope, with a QImaging Retiga 2000R FAST1394 camera.   
 
 
 
 
 
Table 2: Immunostaining targets with corresponding primary and secondary antibodies. Dilutions 
and incubation times and temperatures are given for each individual target.  
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Chapter Three: Results 
c-Met Activation is Dependent on CD82 Expression 
Before the levels of c-Met were measured and compared across cell lines, the 
expression of CD82 in the PC3-#1 and the PC3-29 cell lines needed to be confirmed. An 
adhesion assay was carried out, and the CD82 protein was immunoprecipitated from all 
three experimental cell lines. CD82 produces a broad band centered at approximately 37 
kDa. The PC3-5V do not show evidence of this band, while there is a dark band visible in 
the PC3-#1 and PC3-29 lanes (Figure 3). This indicates that the cell lines containing the 
CD82 vector were expressing CD82 as expected. 
To confirm that each of the three cell lines expressed c-Met under our growth 
conditions, an adhesion assay was carried out. Using collagen as the substrate, both the 
suspension and collected lysates of the samples were transferred to a PVDF membrane 
and stained for total c-Met expression. This includes both the phosphorylated, active form 
of c-Met, and the unprocessed c-Met. The cell suspensions do not show signs of activated 
proteins (Figure 4). Without any matrix to adhere to, there is no signaling through 
integrins. When the cell adheres to a matrix, such as laminin, the amount of signaling 
increases. The substrates used in this study were collagen and laminin. There is a higher 
concentration of both forms of the c-Met protein in the sample from the PC3-5V cell line.  
 The blot seen in Figure 4 was stripped of primary and secondary antibodies, and 
then was stained for total c-Met concentration, rather than total Ptyr. All of the cell lines 
show equal concentrations of total c-Met (Figure 5). As mentioned above, CD82 has not 
been found to interfere with the overall concentration of c-Met. The levels of functional 
c-Met are not dependent on the levels of CD82 found in the cell. The data does 
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demonstrate that CD82 is affecting c-Met activation; cells expressing CD82 have lower 
levels of activated c-Met. The levels of phosphorylated proteins appear to decrease when 
CD82 is returned to physiological levels, demonstrating that CD82 is interfering with 
integrin crosstalk.  
 
 
 
 
 
 
 
 
 
 
Figure 4: Western blot depicting the activation of processed c-Met in the experimental cell lines with 
laminin as a substrate and a PTyr probe. Cells were allowed to adhere to an endogenous matrix until 
adhesion was observed. Lysates were collected and kept frozen at -80ᵒC until use. Lysates were also 
collected from suspensions of each cell line to serve as a control. Protein was analyzed via western 
blot, and stained with 4G10® Platinum, Anti-Phosphotyrosine, Millipore, Product No. 05-1050. 
5VL-PC3 cell line engineered with an empty vector, adhered to the endogenous matrix laminin; 5VS-
PC3 cell line engineered with an empty vector, sample collected from cell suspension for control; 
29L- PC3 cell line engineered with  a CD82-expressing vector, adhered to the endogenous matrix 
laminin; 29S- PC3 cell line engineered with  a CD82-expressing vector, sample collected from cell 
suspension for control. The reduced intensity of the processed c-Met band is indicative of reduced c-
Met activation in the PC3-29 cells.  
Figure 3: Western blot demonstrating the expression of CD82 in the 
experimental cell lines. Suspensions of all three cells lines were lysed 
and the CD82 protein immunoprecipitated. The protein was transferred 
to a PVDF membrane for western blotting. The blot was visualized at 
800nm using a Licor Imaging System.  The 5V cell line carries only an 
empty vector, and does not express CD82. Both PC3-#1 and PC3-29 
cells have vectors that contain functional CD82.  
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Phosphorylation Levels of Tyr1234 and Tyr1235 Are Not Dependent on CD82  
Expression in Experimental Cell Lines  
One of the most common hypotheses regarding the interaction of CD82 and c-Met 
is that CD82 interferes with the phosphorylation of the four sites located at the base of the 
intercellular portion of the growth receptor. To test this hypothesis, an 
immunoprecipitation technique was carried out to analyze the expression levels of the 
activated phosphorylation sites Tyr1234 and Tyr1235 (Figure 6). Analysis of the 
resulting western blot revealed similar levels of phosphorylated protein between the two 
experimental cell lines.  
 
 
 
 
 
 
Figure 5: Western blot depicting the total c-Met found in each of the samples, with laminin as a substrate. 
Cells were allowed to adhere to an endogenous matrix until adhesion was observed. Lysates were collected 
and kept frozen at -80ᵒC until use. Lysates were also collected from suspensions of each cell lines to serve as 
a control. Protein was analyzed via western blot, and stained with c-28 c-Met (Santa Cruz Biotechnology, 
Product No. sc-161). “S” indicates a cell suspension, which serves as a negative control. “L” indicates an 
adhered cell lysate with laminin as a substrate. 
140 kDA (Met) 
200 kDa (pre-Met) 
     5VL          5VS         29L         29S 
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cdc42 Expression Remains Unchanged in the Presence of CD82 Expression in 
Experimental Cell Line 
  cdc42 is a small GTPase with functions that are similar to those of Rac1, and 
whose location in the c-Met signaling pathway are predicted to be the same. 
Immunoprecipitation was carried out to isolate only the activated cdc42 from the sample 
lysates, and the protein was visualized via western blotting. A positive cdc42 cell lysate 
with a His tag attached and a cdc42 cell lysate without the His tag served as positive 
controls. The levels of activated cdc42 appear to be unchanged, both between and within 
the cell lines (Figure 7). However, the presence of a faint band in the negative control 
indicates that a follow-up assay may be necessary.  To confirm the results seen in the 
cdc42 assay, a simplified western blotting procedure, (immunoprecipitating the target 
protein from only the cell suspensions), was carried out to visualize the levels of 
activated cdc42 protein in only the cell suspension samples (Figure 8). The levels of 
Figure 6: Expression levels of phosphorylated Tyr1234 and Tyr1235. These two phosphorylation sites 
are located on the intercellular portion of the c-Met receptor, and begin the signaling cascade that 
eventually leads to Rac1 activation. The levels of PTyr1234 and PTyr 1235 remain constant despite 
CD82 expression. “S” indicates a cell suspension, which serves as a negative control. “CL” indicates an 
adhered cell lysate with collagen as a substrate. 
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activated cdc42 protein appear to be independent of CD82 expression, as the cell 
suspensions and lysates all display comparable levels of the protein. 
 
 
 
 
Figure 7: cdc42 activation assay results showing the expression levels of recombinant cdc42-His, (i.e. the 
positive control with His tag added for identification) and endogenous cdc42 found naturally in the cell 
lines. Lysates from both cell suspensions and adhesion assays were used to analyze the levels of cdc42 
present in the cells, with the cell suspensions serving as a control. The levels of cdc42 remain constant in 
the presence and absence of CD82 expression. Lane borders have been added by the author for clarity. 
Figure 8: cdc42 assay results showing the expression levels of endogenous cdc42 in its activated form, 
using only cell suspensions. Results from the previous assay have been simplified to show the levels of 
activated cdc42 found in the suspensions in the experimental cell lines. The levels of activated cdc42 are 
comparable across the three different cell lines.  
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Correlation of Rac1 Activation With CD82 Expression 
A Rac1 assay was used to isolate the activated form of the Rac1 protein from 
cellular suspesions. Cell suspensions were collected from each of the three cell lines, and 
the activated Rac1 protein was isolated from each of the samples. The isolated protein 
was visualized using standard western blotting techniques. Analysis of the protein levels 
showed higher expression levels of activated Rac1 protein in the PC3-5V suspension 
sample, which does not express CD82 (Figure 9). The PC3-29 and PC3-#1 cell lines both 
express CD82, and these cell lines showed lower levels of activated Rac1 protein than the 
PC3-5V suspension sample. 
 
Visualization of CD82 Expression in Experimental Cell Lines 
The PC3-5V cell line contains an empty vector, and does not express CD82. To 
validate the findings of the c-Met and PTyr activation assays, cell staining was carried 
out to identify which cells were actively expressing CD82. If the activation of c-Met was 
Figure 9: Rac1 assay results showing the expression levels of Rac1 in its activated form in a pull-down 
Rac1 assay using cell suspensions. The western blot show the levels of activated Rac1 found in the 
suspensions in all of the experimental cell lines. The levels of activated Rac1 appear to be elevated in the 
5VS sample, which does not express CD82.  
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truly being influenced by the expression of CD82, there would be observable changes in 
the cytoskeleton. Part of the c-Met signaling pathway includes signaling migration and 
cytoskeletal rearrangement, mediated by Rac1 activation. If the express of CD82 is 
interfering with the activation of either of these proteins, there will be observable 
characteristics. Figure 10B demonstrates the results of the immunofluorescent staining of 
PC3-29 cells for CD82 expression. The staining pattern indicates that CD82 is being 
expressed across the cell membrane, with little fluorescence visible within the cell itself. 
Figure 10A shows the result of CD82 staining for the PC3-5V cells. Little to no 
fluorescence is visible, within the cytosol or on the cell membrane, indicating a lack of 
CD82 expression in the PC3-5V cell line. When it had had been experimentally validated 
that the PC3-29 cells were expressing CD82, the next step was to evaluate cytoskeleton 
changes. 
Figure 10: Visualization of CD82 in experimental cell lines. A) PC3-5V cells were treated with anti-
CD82 antibody [TS82b] Abcam Product No. ab59509. PC3-5V have been transfected with an empty 
vector, and thus do not express CD82 on the surface. B) PC3-29 cells were treated with anti-CD82 
antibody [TS82b] Abcam Product No. ab59509. PC3-29 have been engineered with a vector that 
contains the CD82 expression system. Areas of CD82 expression have been highlighted on the surface 
of the cell.  
A 
B 
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Visualization of F-actin Stress Fibers in Experimental Cell Lines 
 A comparison was made between the actin cytoskeleton arrangement in the 
presence and absence of CD82 expression. This was done by staining the cytoskeleton 
using rhodamine phalloidin to locate F-actin within the cell. Figure 13 depicts the results 
of staining PC3-29 cells with rhodamine phalloidin to visualize the location of F-actin 
fibers, polmerized actin, and stress fibers within the cell. The irregular surface of the cell 
indicates that it has begun to adhere to the endogenous matrix on the cover slip; however, 
there is no evidence of F-actin on the outer edges of the cell. There is a limited amount of 
fluorescence that can be seen towards the center of the cell, but there does not appear to 
be any signifcant structural arrangement. In contrast, Figure 11 shows F-actin fibers 
scattered throughout the cytosol, and is of a higher intensity in the than the PC3-29 cells.  
 
A 
B 
Figure 11: Visualization of F-actin fiber arrangement in experimental cell lines. Both cell lines were 
stained with rhodamine phalloidin to highlight the location of F-actin fibers and focal adhesions with 
the cell and on the cellular membrane. A) Rhodamine phalloidin staining of PC3-5V cells. F-actin 
fibers are visible throughout the entire cytosol, with evidence of focal adhesions forming within the 
cytosol. In the far right micrograph, the cytoskeleton has arranged the F-actin fibers such that the cell 
has formed lammellipodia in preparation for migration. B) Rhodamine phalloidin staining of PC3-29 
cells. The F-actin fibers are concentrated in the center of the cytosol, as well as on the edges. Focal 
adhesions have formed on the edges of the cell membrane indicating the adhesion of the cell to the 
extracellular matrix. Projections are visible along the extracellular membrane as the cell adheres to the 
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Chapter Four: Discussion 
The metastasis of malignant tumors is the leading cause of mortality amongst 
cancer patients (32). Prostate cancer shows a high affinity for metastasis to both brain and 
bone tissue as it progresses to more advanced stages. Metastasis is made possible by two 
factors: the degradation of the extracellular matrix, and the remodeling of the actin 
cytoskeleton. In order for the cells in the primary tumor site to migrate to other tissues, 
they must make their way through the basement membrane and into underlying blood 
vessels. Tumor cells are capable of producing matrix metalloproteins, such as MMP-2, 
MMP-9, and plasmin, to break down the extracellular matrix (60). When the extracellular 
matrix has sufficiently degraded, tumor cells can pass through the basement membrane 
and into blood vessels through a process known as intravasation (60).  
The movement of the tumor cells across the matrix and between the cells lining 
the blood vessels is aided by the arrangement of the actin cytoskeleton. F-actin fibers 
within the cytosol can be arranged to form invasive structures such as lamellipodia and 
filipodia. These invasive projections can be extended from the main cell body, and when 
the cytoskeleton contracts, the cell will migrate across the matrix. The cytoskeleton can 
also be arranged to allow the cell to pass between the tightly connected cells forming the 
blood vessels. Actin fibers will gather along the edges of the cell to prepare for 
lamellipodia formation. 
The growth factor receptor c-Met is responsible for a signaling cascade that 
results in the promotion of metastatic characteristics. These characteristics include 
invasion, migration, proliferation, cell survival, and cytoskeleton rearrangement (Figure 
12). In 2006, a study conducted by Sridhar and Miranti demonstrated that the tumor 
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suppressor protein CD82 is able to regulate c-Met activation in the metastatic prostate 
cancer cell line PC3 (5). Both CD82 and c-Met expression is heavily regulated in normal 
cells. When uncontrolled cell growth progresses to cancer, the downregulation of CD82 
is observed in a variety of cancer types, including prostate cancer (5). Metastatic prostate 
cancer has also demonstrated an overexpression of c-Met (5). When CD82 is restored to 
physiological levels in metastatic prostate cancer cells, the result is a decrease in 
observable metastatic characteristics and the deactivation of important signaling proteins 
(5).  
Structure and Function of c-Met  
The ability to identify proteins and/or signaling molecules involved in prostate 
cancer metastasis would open up an entirely new area of research into drug therapeutics. 
One potential drug target is the c-Met signaling pathway, which has been shown to be 
involved in cancer cell migration and invasion (3). c-Met is a member of the tyrosine 
kinase receptor family, and is found bound in the cellular membrane (29). The receptor is 
composed of two subunits, α and β, that are linked to one another via a disulfide bond 
(29). The β chain is made up of three regions: an extracellular domain, a transmembrane 
region, and cytoplasmic region that extends through the membrane and into the cell itself 
(29). The pathway begins by the binding of the ligand, hepatocyte growth factor (HGF), 
to the membrane-bound receptor on the outside of the cell membrane. c-Met can also be 
activated by integrin signaling within the cell as well. Elevated levels of these integrins 
are associated with tumor formation and metastasis (5). The binding of HGF to the c-Met 
receptor activates the kinase function of the protein, which dimerizes and phosphorylates 
two tyrosine residues at the two key phosphorylation sites this project explored (Tyr 1234 
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and Tyr 1235) (29). The activation of the c-Met receptor results in the phosphorylation of 
four key sites within the cytosol. The phosphorylation of these four sites then sets off a 
signaling cascade, with each subsequent molecule activating the next. When the cascade 
has been triggered, a docking site forms via the phosphorylation of two more tyrosine 
molecules, Tyr 1349 and Tyr 1356. The site is located on the C-terminal tail, and when 
the site is phosphorylated the tyrosine molecules recruit downstream effector molecules 
(61). These major signal relay molecules include Src, growth factor receptor bound 
protein 2 (GRB2), GRB2-associated binding protein 1 (GAB1), phosphoinositide-3-
kinase (PI3K), SHC, SHP2, and signal transducer and activator of transcription 3 
(STAT3) (61) (29). The end result of this cascade is the stimulation of cellular activities 
associated with metastasis, including dissociation, migration, invasion, and cytoskeletal 
rearrangement. 
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Regulation of c-Met Downstream Signaling by CD82 
 The first objective of this study was to identify the phosphorylation site being 
regulated by CD82 expression. The levels of activated c-Met have been shown to be 
dependent on the expression of CD82 in the experimental cell lines, both in previous 
research and in this study (Figure 4) (5). The PC3-5V, which do not express CD82, have 
significantly higher levels of activated c-Met in the sample. The c-Met protein was 
isolated from cell suspensions and adhered cell lysates, and then treated with a PTyr 
Figure 12: Extended diagram showing the full c-Met signaling pathway. The binding of hepatocyte growth 
factor (HGF) leads to the phosphorylation of four key sites within the cytosol, which initiates a signaling cascade 
that stimulates cellular activities associated with tumor metastasis, such as dissociation, migration, invasion, and 
cytoskeletal rearrangement.  
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probe. This probe is used to highlight the presence of phosphorylated proteins. The use of 
the PTyr probe assumes the phosphorylation of c-Met is equivalent with activation. There 
is a higher concentration of phosphorylated proteins in the cell line that is lacking CD82 
expression. This is demonstrated by the increased band intensity at 140 kDa in the 5VL 
sample (Figure 4). Integrin signaling is silenced when the cells are not adhered to a 
matrix. The cell suspensions do not show any evidence of activated c-Met. The levels of 
activated c-Met appear to decrease in the presence of CD82 expression in PC3 cell lines 
(Figure 4).  
 While CD82 may play a role in the regulation of c-Met activation, it does not 
appear to affect the overall expression of c-Met (Figure 5). The levels of total c-Met 
present in the cell lines was observed using a total Met probe. There is an important 
distinction that must be made between the probe used to observe total c-Met and the PTyr 
probe. As mentioned previously, the PTyr probe is used to look at phosphorylated 
proteins that have been isolated from samples using immunoprecipitation. The total Met 
probe also requires immunoprecipitation, but it cannot differentiate between active and 
inactive c-Met. Therefore, the results of the total c-Met western blot cannot be used to 
draw conclusions regarding the activated state of c-Met. The levels of total c-Met do not 
appear to change in the presence of CD82 expression (Figure 5). The 140 kDa band 
produced by the total Met probe does not lose intensity between the PC3-5V and PC3-29 
cell lines (Figure 5). This indicates that the production of c-Met is not dependent on 
CD82 expression, but CD82 does appears to be regulating c-Met activation.  
 This research project was successful at demonstrating that the expression of the 
tumor suppressor protein CD82 is regulating the activation of c-Met without influencing 
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the overall production of c-Met. The relationship between CD82 expression and c-Met 
observed in this study is supported by previous literature (5). An interesting question 
posed by these results is if this relationship would prove to be true across different types 
of extracellular matrix proteins. Laminin was used to look at the activation of c-Met, 
while collagen was used to investigate the PTyr 1234/1235 phosphorylation site. There 
was no noticeable change in the level of phosphorylation between the different cell lines. 
Further research would include using both laminin and collagen for the PTyr 1234/1235 
phosphorylation sites. For example, in addition to exploring PC3 cellular adhesion to 
collagen, laminin, and fibronectin, further research could be done using attachment factor 
protein matrix. This matrix contains gelatin as an attachment factor, and enhances the 
growth of endothelial cells. If the starved cells are placed on a surface that has been 
coated with an attachment factor, it is possible that even cells displaying migratory 
characteristics would demonstrate higher levels of attachment. An increase in the binding 
affinity of the cell to the substrate could have an observable effect on metastatic 
characteristics, as well as the levels of activated c-Met found in the cells.  
 
Regulation of c-Met Phosphorylation by CD82  
 The second objective of this study was to identify the specific c-Met 
phosphorylation site being regulated by CD82 in PC3 cells. A special focus was placed 
on the Tyr1234/1235 phosphorylation site. This is one of four sites that become 
phosphorylated once c-Met is activated by the binding of HGF or integrin activation. 
Tyr1234/1235 was chosen due to previous research showing that AKT and ERK are not 
affected by CD82 expression in PC3 cells (5). The activation of AKT and ERK can be 
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traced to their respective phosphorylation sites, neither of which includes the 
Tyr1234/1235 site. Preliminary data suggest that CD82 does not affect the 
phosphorylation of the other three sites, indicating that the activation of Tyr1234/1235 
could be dependent on CD82 expression. This possible relationship was explored by 
immunoprecipitating c-Met, isolating Tyr1234/1235 from the cell lysates and probing for 
phosphorylated proteins. The phosphorylated version of Tyr1234/1235 creates a band at 
approximately 140kDa when run through an SDS-PAGE gel. There is a distinct band 
visible at 140 kDa in both the experimental and control cells, indicating the presence of 
phosphorylated Tyr1234/1235 protein (Figure 6). The intensity of this band remains 
constant across the four sample lanes. There does not appear to be any differential 
phosphorylation amongst the cell lines. The expression of CD82 does not seem to have 
an effect in the phosphorylation of the Tyr1234/1235 site.   
 From the data collected by this project, it can be determined that the 
phosphorylation of Tyr1234/1235 site was not affected by CD82 expression. However, 
this study was unsuccessful at determining which c-Met phosphorylation site is being 
regulated by CD82. If the phosphorylation of the Tyr1234/1235 site is not being 
regulated by the expression of CD82, the question remains as to which site is being 
regulated by CD82 expression. Considering the preliminary studies mentioned at the 
beginning of this section, it suggests the question if the phosphorylation of the four key 
sites is being affected by CD82 expression. In non-small cell lung carcinoma and oral 
squamous cell carcinoma, CD82 was found to attenuate the association between c-Met 
and several adaptor molecules, such as Grb2 and p85 (62). The arrangement of the actin 
cytoskeleton observed when CD82 is expressed suggests that CD82 is interfering with 
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migratory signaling. Cell migration is a complex phenomenon that is regulated by 
adaptor proteins, which recruit GTP-binding proteins cdc42, Rho, and Rac1 (62). Rather 
than interfere with the phosphorylation of the initial four sites, it is plausible that CD82 is 
instead regulating the recruitment of adaptor proteins. This hypothesis could be validated 
by observing the levels of adaptor proteins such as p85 and Grb2, which are responsible 
for activating cdc42 and Rac1, in each of the experimental cell lines. If CD82 expression 
is associated with lower levels of adaptor proteins, it would provide an explanation as to 
why the phosphorylation of the four key sites in c-Met remain unchanged in the presence 
of CD82.    
 
CD82 Expression Regulates Downstream Signaling Events in the c-Met Signaling 
Pathway 
 The decision to explore the relationship between CD82 expression and Rac1 
activation was influenced by previous research. As mentioned before, a study published 
in 2006 demonstrated that the ERK and AKT pathways were not influenced by CD82 
expression in PC3 cells (5). Even if CD82 was interfering upstream in these two 
pathways, it would still not have the observed impact on migration and invasion 
characteristics. The activation of ERK is required for cell proliferation, and AKT 
activation leads to the development of survival characteristics in prostate cancer cells. 
Previous research conducted in our lab showed that the expression of CD82 in prostate 
cancer led to observable effects in the arrangement of the actin cytoskeleton. The ability 
of CD82 to influence the formation of F-actin fibers, polymerized actin, and stress fibers 
and their arrangement suggests that CD82 is interfering with a portion of the c-Met 
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signaling pathway involved in cell motility. Rac1 is a small Rho GTPase that is involved 
in cell motility and actin cytoskeleton reorganization (Figure 12). The role of Rac1 in the 
recruitment of F-actin fibers and chemotaxis has been well documented (63). This makes 
an ideal target for CD82 interaction, as the result of Rac1 inactivation is poor cell motility 
(63). The protein cdc42 also plays a role in cell migration, and due to its similarity to 
Rac1 in size and function, cdc42 activation was investigated.  
 
cdc42 Expression Remains Unchanged in the Presence of CD82 Expression in 
Experimental Cell Lines 
 cdc42 is one of three Rho GTPases that are involved in the c-Met signaling 
pathway. Rho GTPases are involved in regulating the dynamics involved in cell adhesion 
and the actin cytoskeleton (64). The expression of these GTPases are often altered during 
the formation of malignant tumors, but researchers are still working to determine the 
exact way they perform their regulatory functions (65). Previous studies have shown that 
cdc42 promotes the attachment of cancer cells to endothelial tissue and the basement 
membrane by influencing the cells during the transendothelial migration of tumor cells 
(65). This invasion strategy is made possible by cdc42 upregulating the expression of the 
adhesion receptor known as β1 integrin, a receptor that has already been shown to play a 
role in cancer metastasis (66). When cdc42 expression is reduced in metastatic tumor 
cells, the cancer cells fail to invade the basement membrane and form attachments to the 
surrounding tissue (65).  
 All three of the PC3 cell lines used in this study are prostate cancer cells derived 
from bone metastasis. A cdc42 activation assay was carried out on all three of the cell 
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lines, two of which carried a vector containing a function copy of the CD82 gene (PC3-
29 and PC3-#1). The levels of activated cdc42 within the CD82-expressing cells, (PC3-
#1 and PC3-29), were compared against the levels found in the PC3-5V cells in order to 
see if CD82 was interfering with the activation of cdc42. It was found that the level of 
activated cdc42 did not vary amongst the three different cell lines, nor did it appear to 
vary between adhered lysates and cell suspensions (Figure 8). If CD82 was influencing 
the activation of cdc42, there would be higher levels of activated cdc42 in the PC3-5V 
cells, both in the suspension and the adhered lysates. Despite its role in cell migration and 
invasion in metastatic prostate cancer, our results indicate that cdc42 activation is not 
dependent on the expression of a functional CD82 gene (67). It should be noted that a 
faint band does appear in the negative control lane. This is most likely due to 
experimental error. However, to confidently state the results of the cdc42 assay, the assay 
would need to be repeated. The cdc42 activation assay using just the cell lysates does not 
display any change in activation in the presence of CD82 expression. This lends evidence 
to the hypothesis that the expression of CD82 is interfering with the activation of the 
Rac1 protein, which also plays a major role in invasion and migration in the c-Met 
signaling pathway.  
 
Rac1 Activation in CD82-Expressing Cell Lines 
 The activation of Rac1 and related GTPases is required for the assembly and 
placement of the actin fibers that make up the cytoskeleton (56). The up-regulation of c-
Met in prostate cancer correlates with an increase in the activation of downstream 
effector molecules, such as Rho, cdc42, and Rac1. It was demonstrated that the levels of 
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cdc42 remain constant whether or not CD82 is being expressed by the cell (Figure 8). 
This evidence indicates that the decrease in migration seen in the PC3-29 and PC3-#1 
cells is not due to CD82 interfering with cdc42. Because there is an observed change in 
the arrangement of F-actin fibers in the cytosol, CD82 must be affecting the activation of 
the signaling molecule necessary for migration. Rac1 has also been shown to play a role 
in the arrangement of the actin cytoskeleton prior to invasion. The isolation of Rac1 from 
each of the three experimental cell lines showed a slight increase in the concentration of 
activated Rac1 in the PC3-5V cell suspension (Figure 9). PC3-5V does not express 
CD82. PC3-#1 and PC3-29, have been engineered to carry a vector with a functional 
copy of CD82. The levels of activated Rac1 appear to decrease in the presence of CD82 
in cell suspensions. It should be made clear that the decrease in Rac1 activation seen in 
this research applies only to the cell suspensions. The cdc42 activation assay was 
performed on both adhered cell lysates and cell suspensions. The apparent decrease in 
Rac1 activation seen in Figure 9 is only relevant when put into the context of the cell 
suspensions. More research is needed to determine if CD82 is involved in the 
downstream regulation of Rac1 activation by CD82.  
 
CD82 is Expressed on the Peripheral Cell Surface in PC3-29 Cells 
 To test for a correlation between CD82 expression and cytoskeletal changes, it 
was critical that the expression of CD82 could be visualized in the experimental cell lines 
that were engineered to express it. Both cell lines were treated with anti-CD82 antibody 
[TS82b] Abcam Product No. ab59509, and visualized using a FIT-C filter under an oil-
immersion lens. CD82 is a tumor suppressor protein that is categorized as a tetraspanin 
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protein, having four distinct regions that are embedded in the cell membranes of multi-
cellular organisms (18). It is expressed in the cell membranes of all healthy tissues, but its 
expression is down-regulated or nonexistent in cancer cells, particularly in prostate 
cancer cells (7). PC3-5V showed little to no evidence of CD82 expression on the cell 
surface (Figure 10A). Even when the contrast of the micrographs was enhanced, there 
was no sign of CD82 expression at the cell surface in the PC3-5V (Figure 10A). In 
contrast, the PC3-29 cells showed high levels of CD82 expression (Figure 10B). Much of 
the CD82 expression could be seen along the edges of the cell membrane, particularly in 
those cells that showed the development of adhesive filaments (Figure 11B).  
 
Lack of CD82 Expression Leads to Invasive Cytoskeletal Changes 
 Much as the human skeleton supports the structure of the body, the cytoskeleton 
supports the structure of the cell body. Changes in the actin cytoskeleton are required for 
a cancer cell to metastasizes beyond its native tissue. The remodeling of the cytoskeleton 
involves the production and arrangement of polymerized actin, the creation of stress 
fibers, and the overall formation of lamellipodia. PC3-5V cells were stained with 
rhodamine phalloidin to visualize F-actin fibers and stress fibers. Rhodamine phalloidin 
is a high-affinity F-actin probe that can be used to stain for both F-actin fibers and focal 
adhesions within the cell and on the cell surface. Staining of PC3-5V show that actin 
fibers are visible through the cytosol, with little evidence of focal adhesion formation 
(Figure 11A). Adhesive filaments are not visible on the edges of the cell, indicating that 
the cell is preparing to migrate. The micrograph on the right shows the formation of 
lamellipodia; the cell is beginning to take on a sickle-shaped appearance, and actin fibers 
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have begun to congregate along the edge of the cell and the tip of the lamellopodia 
(Figure 11A).  
 
CD82 Expression Leads to Development of Adhesion Characteristics 
All PC3-29 cells displayed in the micrographs show signs of adhesive filaments 
forming around the edge of the cell, indicating that the cell has begun to adhere to the 
endogenous matrix (Figure 11B). The F-actin fibers are concentrated in the center of the 
cytosol, with a structured scaffolding extended to the edges of the cell (Figure 11B). 
Overall, the cytoskeletons of the PC#-29 cells are far more organized than the PC3-5V 
cells. The PC3-5V cells do not show signs of adhering to the matrix. They demonstrate 
evidence of cellular structures that are associated with invasion and migration. The 
difference in the cytoskeletal organization between the two cell lines is assumed to be the 
expression of CD82. This lends evidence to the hypothesis that CD82 is interfering with 
the c-Met signaling pathway involved in cytoskeletal rearrangement, invasion, and 
migration.  
In addition to interfering with the activation of Rac1, further research could be 
done to investigate other migratory characteristics affected by CD82. Not only would it 
be interesting to look at other physical structures, such as F-actin protrusions, levels of E-
cadherin could be studied. There is also the possibility that CD82 has a regulatory 
function in another pathway involved in cancer cell metastasis, such as fibroblast growth 
factor pathways (68). The evidence gained from this study demonstrates no apparent 
decrease in cdc42 activation, leading to the hypothesis that CD82 could have other 
regulatory roles. In 2015, a study showed that the expression of CD82 reduces the 
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adhesion of cancer cells to blood vessels in Sialyl Lewis antigen-mediated adhesion (8). 
It is clear that CD82 has regulatory functions outside of preventing the rearrangement of 
the actin cytoskeleton needed for metastasis that are worth investigating.  
 
Overall Conclusions  
 The results of this study indicated that CD82 has a regulatory effect on c-Met 
activation. The overall levels of total c-Met remain unchanged in the presence of CD82, 
but the expression of CD82 leads to a decrease in the expression of activated c-Met. 
While this project was unable to identify the specific c-Met phosphorylation site being 
regulated by CD82, the evidence suggests that the Tyr1234/1235 remains unaffected by 
CD82 expression. CD82 does appear to influence downstream events in the c-Met 
signaling pathway. We have shown that the levels of cdc42 expression do not change 
across the three experimental cell lines, and remain constant in suspension as well. We 
investigated the levels of activated Rac1 in cell suspensions, and the levels of activated 
Rac1 appear to decrease with CD82 expression. Further research is needed to 
conclusively state whether CD82 is influencing the activation of Rac1 in the c-Met 
signaling pathway. The results of this study provide evidence to suggest that CD82 is 
playing a role in regulating the formation of metastatic characteristics in PC3 cells. 
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Chapter Five: Research Summary 
 This project focused on the role of the metastasis suppressor protein CD82 in the 
deactivation of the c-Met signaling pathway in metastatic prostate cancer. Prostate cancer 
is currently the second leading cause of death among men in the United States (1). There 
are two key players in the metastasis of prostate cancer: tumor suppressor proteins, and 
growth factor receptors. Tumor suppressor genes are expressed in normal, healthy cells, 
and serve as key regulators of the cell cycle. A mutation in these genes often lead to a 
loss or reduction in function, which allows cells to transition into malignant tissues. The 
loss of the tumor suppressor protein CD82 has been implicated in approximately 70% of 
prostate cancer cases and has been linked to metastasis and poor patient prognosis (69).  
Growth factor receptors also play a major role in the regulation of growth signals 
in normal cells. The importance of their function means that they are highly regulated in 
healthy cells. The overexpression of growth factors has been observed in many different 
types of cancer, including prostate cancer. Of the many growth factors, whose 
malfunction has been linked to the development of cancer, c-Met is a particularly 
attractive target for prostate cancer therapeutics. c-Met has one endogenous ligand: 
hepatocyte growth factor (HGF). When HGF binds to the c-Met receptor on the 
extracellular surface of the cell, it signals the beginning of a metastatic cascade. This 
cascade can also be initiated by engaging integrins. The activation of c-Met leads to the 
phosphorylation of four key sites connected to the β-subunit of the c-Met receptor: 
pY1003, pY1234/1235, pY1349, and pY1356. The phosphorylation of these four sites 
leads to the recruitment of downstream effector molecules that trigger metastatic 
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characteristics in prostate cancer such as invasion, migration, cell adhesion, and actin 
cytoskeleton re-arrangement (Figure 1).  
 The first objective in this study was to determine which downstream signaling 
pathway found in c-Met was being regulated by CD82. The levels of total c-Met appear 
to remain unchanged in the presence of CD82 expression. However, CD82 does appear to 
be regulating the activation of c-Met. There are decreased levels of activated c-Met in the 
cell lines that are expressing CD82. Overall, this study was successful at concluding that 
CD82 expression is regulating the activation of c-met, but not the overall production of c-
Met. 
 Identification of the specific c-Met phosphorylation site being regulated by CD82 
proved to be rather difficult. The Tyr1234/1235 phosphorylation site was chosen for 
investigation due to previous research suggesting the other three sites are unaffected by 
CD82 expression. The results of this study indicate that the phosphorylation of the 
Tyr1234/1235 site is not regulated by CD82 expression. There is no differential 
phosphorylation of Tyr1234/1235 amongst the cell lines used in this study. We were 
unsuccessful at determining which c-Met phosphorylation site is being regulated by 
CD82, if any. The question does arise as to whether the phosphorylation of these four 
sites is being regulated by CD82 expression. Further study is needed to determine which 
site, if any, is regulated by CD82.  
 The final objective of this study was to identify the overall downstream event that 
is being regulated by CD82. Previous research showed that the expression of CD82 led to 
observable changes in the cytoskeleton of the cell lines. The GTPase known as Rac1 was 
investigated as being regulated by CD82 expression. Rac1 is involved in the signaling of 
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actin cytoskeleton rearrangement and cell motility. cdc42 is a protein of similar size and 
function to Rac1, and the effect of CD82 expression on cdc42 was also investigated. The 
levels of activated cdc42 appear to be unchanged in the presence of CD82. Levels of 
activated Rac1 in the cell suspensions appeared to decrease with CD82 expression. While 
the suspensions appear to indicate an inverse relationship between Rac1 activation and 
CD82 expression, the results remain inconclusive. Further research is needed to look at 
the levels of activated Rac1 in both cell suspensions and adhered cell lysates. The 
expression of CD82 also appears to the lead to the development of adhesion 
characteristics. PC3-29 cells demonstrated the formation of actin projections that suggest 
adherence to the substrate. They also displayed fewer stress fibers and polymerized actin. 
The lack of CD82 expression in the PC3-5V cells appears to lead to the development of 
invasive cytoskeletal changes. The PC3-5V showed evidence of more stress fibers and 
polymerized actin than seen in the PC3-29 cells. PC3-29 cells showed evidence of 
adhering to the substrate, whereas the PC3-5V cells demonstrated physical characteristics 
that indicate cell migration.  
 The ability of CD82 to associate with other proteins and regulate their functions is 
an important aspect of research into prostate cancer metastasis. The results of this study 
indicate that CD82 appears to be regulating the development of migratory characteristics 
associated with the activation of the growth factor receptor known as c-Met. Specifically, 
CD82 appears to be interacting with the GTPase Rac1, a signaling molecule that has been 
shown to have a role in cell motility. Further research is needed to validate the 
relationship between CD82 expression and Rac1 activation, but this study provides 
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important information regarding the regulatory function of CD82 in prostate cancer 
metastasis.  
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Chapter Six: Future Directions 
 
While this project represents an investigation into the role of CD82 as an inhibitor 
of Rac1 in the c-Met signaling pathway, there still much that remains to be explored. A 
more exhaustive analysis of Rac1 activation in prostate cancer cell lines is required to 
support the conclusions drawn by this research. Part of this analysis would include 
performing a large scale Rac1 activation assay on the three experimental PC3 cell lines. 
Rac1 is a very difficult protein to isolate from cell lysates, as it is only expressed for a 
limited amount of time while the actin fibers of the cytoskeleton are being rearranged. A 
more thorough assay would involve plating multiple plates of the same cell line and 
harvesting the lysates from those cells at different time points. This would give more 
information as to how long it takes Rac1 to be activated and how long it is expressed in 
the presence and absence of CD82. The actual activation of Rac1 could be traced in real 
time, and conclusions drawn regarding the effect of CD82 expression on its activation. 
Based on the results of this investigation, one would expect to see a decrease in Rac1 
activation in the cell lines that express physiological levels of CD82 if it is serving as an 
inhibitor (as seen in Figure 9).  
Validation of the small-scale assay could then be followed by attempting to 
quantify the decrease in Rac1 activation between PC3-29 cell sand PC3-5V cells. 
Quantifying the effect that CD82 has on the activation of Rac1 could be instrumental in 
developing a more effective inhibitor of Rac1 and related Rho GTPases in the future. The 
effect of CD82 expression should also be compared across prostate cancer cell lines, and 
potentially across different kinds of human cancers, to see if the inverse relationship 
between CD82 expression and Rac1 activation holds true.  
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 There still are questions to be answered regarding the effect of CD82 
expression on the phosphorylation of the four key sites on the c-Met receptor. When 
placed in the context of previous research studies, the results of this study suggest that 
CD82 does not interfere with the phosphorylation of those four sites. This raises the 
question of whether CD82 is interfering with phosphorylation at all. It also demonstrates 
a need to investigate if phosphorylation is an adequate method for determining the 
activation levels of c-Met.  
In addition to observing F-actin fibers, future work could potentially include 
observing other invasive characteristics seen in metastatic prostate cancer. This would 
include the development of F-actin protrusions and measuring the levels of E-cadherin in 
the cells. There is also the possibility that CD82 possess another regulatory function that 
has yet to be described. A better understanding of how small Rho GTPases become 
inhibited by tumor suppressor proteins such as CD82 could potentially lead to the 
development of more effective chemotherapies capable of targeting metastatic 
characteristics.  
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